Inceptionr LLC Invests $477,000 in Azenta, Inc. $AZTA

Inceptionr LLC acquired a new stake in shares of Azenta, Inc. (NASDAQ:AZTA) in the first quarter, HoldingsChannel reports. The fund acquired 22,576 shares of the company’s stock, valued at approximately $477,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd boosted its stake in Azenta by 2,067.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 802 shares of the company’s stock valued at $27,000 after acquiring an additional 765 shares during the period. Assetmark Inc. raised its position in shares of Azenta by 54.1% during the 4th quarter. Assetmark Inc. now owns 832 shares of the company’s stock worth $28,000 after purchasing an additional 292 shares during the period. State of Wyoming acquired a new stake in shares of Azenta during the 1st quarter worth approximately $38,000. Osaic Holdings Inc. lifted its holdings in shares of Azenta by 44.9% in the 2nd quarter. Osaic Holdings Inc. now owns 1,242 shares of the company’s stock worth $39,000 after purchasing an additional 385 shares during the last quarter. Finally, Rockefeller Capital Management L.P. boosted its position in Azenta by 98.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,392 shares of the company’s stock valued at $46,000 after purchasing an additional 689 shares during the period. Institutional investors and hedge funds own 99.08% of the company’s stock.

Azenta Stock Performance

Shares of NASDAQ AZTA opened at $27.37 on Monday. Azenta, Inc. has a 12-month low of $15.93 and a 12-month high of $41.73. The company has a market cap of $1.26 billion, a PE ratio of -6.91 and a beta of 1.37. The stock has a 50 day simple moving average of $23.69 and a 200-day simple moving average of $26.05.

Azenta (NASDAQ:AZTA) last posted its earnings results on Wednesday, May 6th. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of $0.12 by ($0.16). The business had revenue of $144.79 million during the quarter, compared to analyst estimates of $148.47 million. Azenta had a negative net margin of 30.49% and a positive return on equity of 1.23%. The firm’s revenue was up 1.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.01 earnings per share.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on AZTA shares. Weiss Ratings upgraded Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. Needham & Company LLC reduced their price target on shares of Azenta from $44.00 to $33.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Azenta has a consensus rating of “Hold” and a consensus target price of $40.40.

About Azenta

Azenta, Inc (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.

In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services.